Treace Medical Concepts Management
Management criteria checks 3/4
Treace Medical Concepts' CEO is John Treace, appointed in Jul 2014, has a tenure of 10.83 years. total yearly compensation is $6.60M, comprised of 11% salary and 89% bonuses, including company stock and options. directly owns 18.61% of the company’s shares, worth $78.66M. The average tenure of the management team and the board of directors is 3.7 years and 7.3 years respectively.
Key information
John Treace
Chief executive officer
US$6.6m
Total compensation
| CEO salary percentage | 10.97% |
| CEO tenure | 10.8yrs |
| CEO ownership | 18.6% |
| Management average tenure | 3.7yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
We Discuss Why Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) CEO Compensation May Be Closely Reviewed
May 13
Treace Medical Concepts, Inc. (NASDAQ:TMCI) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 11Treace Medical Concepts: No Solid Footing
Apr 07
New Bunion Treatments Will Open Broader Market Opportunities
Innovative products and expanded portfolio aim to penetrate the U.S. bunion market and enhance revenue through increased surgeon adoption and market appeal.Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Rockets 26% But Many Are Still Ignoring The Company
Jan 18Further Upside For Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Could Introduce Price Risks After 84% Bounce
Dec 03Is Treace Medical Concepts (NASDAQ:TMCI) Using Debt In A Risky Way?
Oct 26Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch
Aug 02Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?
Jun 28Treace Medical Concepts: Facing Increasing Competitive Pressure
Jun 14Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)
Apr 05Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?
Feb 09Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge
Jan 04Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$7m | US$723k | -US$56m |
| Sep 30 2024 | n/a | n/a | -US$62m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$8m | US$684k | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$47m |
| Dec 31 2022 | US$4m | US$568k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$45m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$27m |
| Dec 31 2021 | US$688k | US$410k | -US$21m |
| Sep 30 2021 | n/a | n/a | -US$12m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$392k | US$316k | -US$4m |
Compensation vs Market: John's total compensation ($USD6.60M) is above average for companies of similar size in the US market ($USD2.68M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Treace (52 yo)
10.8yrs
Tenure
US$6,597,160
Compensation
Mr. John T. Treace Founded Treace Medical Concepts, Inc. in 2014 and has been its Chief Executive Officer and Director since July 1, 2014. Before that, Mr. Treace served as Senior Vice President of U.S. Sa...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Founder & Director | 10.8yrs | US$6.60m | 18.61% $ 78.7m | |
| Chief Financial Officer | 4.7yrs | US$4.49m | 0.081% $ 341.8k | |
| Chief Legal & Compliance Officer and Corporate Secretary | 3.6yrs | US$4.55m | 0.085% $ 358.7k | |
| Chief Innovation Officer | 2.3yrs | US$3.09m | 0.062% $ 262.0k | |
| Chief Commercial Officer | less than a year | US$3.23m | no data | |
| Chief Operations & Supply Chain Officer | 3.7yrs | no data | no data | |
| Chief Information & Cybersecurity Officer | 3.2yrs | no data | no data | |
| Senior Vice President of Sales | 3.8yrs | US$3.26m | 0.013% $ 53.1k | |
| Chief Human Resources Officer | 4.3yrs | no data | no data | |
| Senior Vice President of Clinical Affairs & Reimbursement | no data | no data | no data | |
| Chief Strategic Initiatives Officer | no data | no data | no data |
3.7yrs
Average Tenure
52yo
Average Age
Experienced Management: TMCI's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Founder & Director | 10.8yrs | US$6.60m | 18.61% $ 78.7m | |
| Independent Director | 4.5yrs | US$224.78k | 0.0080% $ 33.9k | |
| Chairman of the Board | 10.9yrs | US$99.78k | 2.83% $ 12.0m | |
| Lead Independent Director | 10.2yrs | US$225.73k | 1.68% $ 7.1m | |
| Independent Director | 4.5yrs | US$224.78k | 0.76% $ 3.2m | |
| Independent Director | 3.6yrs | US$224.56k | 0.049% $ 207.3k | |
| Member of the Surgeon Advisory Board | no data | no data | no data | |
| Member of the Surgeon Advisory Board | no data | no data | no data | |
| Member of the Surgeon Advisory Board | no data | no data | no data | |
| Member of the Surgeon Advisory Board | no data | no data | no data | |
| Member of the Surgeon Advisory Board | no data | no data | no data | |
| Member of the Surgeon Advisory Board | no data | no data | no data |
7.3yrs
Average Tenure
63.5yo
Average Age
Experienced Board: TMCI's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 01:27 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Treace Medical Concepts, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Lilia-Celine Lozada | J.P. Morgan |
| Robert Marcus | J.P. Morgan |